[1]CurrentPatentAssignee:CHONGKUNDANGPHARMACEUTICALCORP.-KR2021/30109,2021,ALocationinpatent:Paragraph0164-0280;0289-0338
[2]CurrentPatentAssignee:SKCAPITALPARTNERSLP-US2018/179226,2018,A1Locationinpatent:Paragraph0368
[3]CurrentPatentAssignee:BORYUNGPHARMCO.,LTD.;BORYUNG-WO2022/103239,2022,A1Locationinpatent:Paragraph47-48;141;151-153;154;171-172
[4]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2371830,2011,A1Locationinpatent:Page/Pagecolumn9-10
[5]CurrentPatentAssignee:CHINACHEMICALPHARMACEUTICALGROUP;CHUNGWHACHEMICALSYNTHESISBIOTECH-TWI571460,2017,BLocationinpatent:Paragraph0042-0043
[6]CurrentPatentAssignee:BEIJINGSUNNOVOPHARMACEUTICALRES-CN108484641,2018,ALocationinpatent:Paragraph0066-0069;0097-0098
[7]CurrentPatentAssignee:INNERMONGOLIAJINGDONGPHARMACEUTICAL-CN111393456,2020,ALocationinpatent:Paragraph0099-0101
[8]CurrentPatentAssignee:GLENMARKPHARMACEUTICALSLTD-WO2021/1728,2021,A1Locationinpatent:Paragraph19-20
[9]CurrentPatentAssignee:VIATRISINC-WO2018/11823,2018,A1Locationinpatent:Page/Pagecolumn28
[10]CurrentPatentAssignee:HARBINPHARMACEUTICALGROUPCO.,LTD.-CN114736218,2022,ALocationinpatent:Paragraph0040-0044;0053-0054
[11]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP1405852,2004,A1Locationinpatent:Page424
[12]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2407450,2012,A1Locationinpatent:Page/Pagecolumn21-22
[13]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2407457,2012,A1Locationinpatent:Page/Pagecolumn17
[14]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2589590,2013,A1Locationinpatent:Paragraph0146;0147
[15]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-US2013/144061,2013,A1Locationinpatent:Paragraph0264;0265;0266;0267;0268;0269;0270
[16]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-US2015/353577,2015,A1Locationinpatent:Paragraph0099;0100
[17]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-JP5801011,2015,B2Locationinpatent:Page/Pagecolumn0214-0216
[18]CurrentPatentAssignee:SHENZHENKEXINGBIOTECH;SHANDONGKEXINGBIOPRODUCTS-CN104761571,2017,BLocationinpatent:Paragraph0063;0064;0065
[19]CurrentPatentAssignee:CorporacionQuimicoFarmaceuticaEsteveSA-WO2018/83213,2018,A1Locationinpatent:Page/Pagecolumn13
[20]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-US2017/22220,2017,A1Locationinpatent:Paragraph0050;0051;0052;0053;0054;0055;0056
[21]CurrentPatentAssignee:JIANGSUWEIKELMEDICALTECH-CN114349770,2022,ALocationinpatent:Paragraph0057-0062
[22]CurrentPatentAssignee:BORYUNGPHARMCO.,LTD.;BORYUNG-WO2022/103239,2022,A1Locationinpatent:Paragraph47-48;141;151-153-154;171-172
[23]CurrentPatentAssignee:SHANGHAIBIOSBIOTECHNOLOGY-CN115724792,2023,ALocationinpatent:Paragraph0095-0110
[24]CurrentPatentAssignee:BORYUNGPHARMCO.,LTD.;BORYUNG-WO2022/103239,2022,A1Locationinpatent:Paragraph47-48;141;151-153-154;171-172
[25]CurrentPatentAssignee:ZHEJIANGJIUZHOUPHARMCOLTD-CN116332958,2023,ALocationinpatent:Paragraph0054-0056
[1]CurrentPatentAssignee:INNERMONGOLIAJINGDONGPHARMACEUTICAL;BEIJINGSIHUANKEBAOPHARMACEUTICAL-CN109942600,2019,ALocationinpatent:Paragraph0239-0241
[2]CurrentPatentAssignee:INNERMONGOLIAJINGDONGPHARMACEUTICAL-CN111393456,2020,ALocationinpatent:Paragraph0091-0096
[3]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP1683800,2006,A1Locationinpatent:Page/Pagecolumn59;60
[4]CurrentPatentAssignee:CHUNGWHACHEMICALSYNTHESISBIOTECH;CHINACHEMICALPHARMACEUTICALGROUP-TWI571460,2017,BLocationinpatent:Paragraph0040-0041
480452-36-6
[1]CurrentPatentAssignee:BEIJINGSUNNOVOPHARMACEUTICALRES-CN108484641,2018,ALocationinpatent:Paragraph0050-0055;0089-0096
[2]CurrentPatentAssignee:MOEHSIBERICASL-WO2019/158550,2019,A1Locationinpatent:Page/Pagecolumn15-16
[3]CurrentPatentAssignee:VIATRISINC-WO2018/11823,2018,A1Locationinpatent:Page/Pagecolumn27
[4]CurrentPatentAssignee:GLENMARKPHARMACEUTICALSLTD-WO2021/1728,2021,A1Locationinpatent:Page/Pagecolumn17-18
[5]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP1925611,2008,A1Locationinpatent:Page/Pagecolumn47-48
[6]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2407450,2012,A1Locationinpatent:Page/Pagecolumn21
[7]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2407457,2012,A1Locationinpatent:Page/Pagecolumn16
[8]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2589590,2013,A1Locationinpatent:Paragraph0144;0145
[9]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-WO2014/81047,2014,A1Locationinpatent:Page/Pagecolumn22
[10]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-US2015/353577,2015,A1Locationinpatent:Paragraph0097;0098
[11]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-JP5801011,2015,B2Locationinpatent:Page/Pagecolumn0210-0212
[12]CurrentPatentAssignee:SHANDONGKEXINGBIOPRODUCTS;SHENZHENKEXINGBIOTECH-CN104761571,2017,BLocationinpatent:Paragraph0049;0050;0051;0052;0053
[13]CurrentPatentAssignee:GAPIBIO;DONGBANGFTL;GABIBIO-JP2019/210273,2019,ALocationinpatent:Paragraph0043;0048
[14]CurrentPatentAssignee:ZHEJIANGSUPORPHARMACEUTICALSCOLTD-CN111606927,2020,ALocationinpatent:Paragraph0023-0062
[15]CurrentPatentAssignee:PHARMACOSTECHCOLTD-KR2021/152213,2021,ALocationinpatent:Paragraph0055-0057;0060;0062
[1]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2383272,2011,A1Locationinpatent:Page/Pagecolumn6-7
[2]CurrentPatentAssignee:DONG-ASTCO.,LTD.-KR2020/53270,2020,ALocationinpatent:Paragraph0221-0222
[1]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2407450,2012,A1CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2407457,2012,A1
[2]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2407457,2012,A1
[3]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-EP2589590,2013,A1
[4]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-US2015/353577,2015,A1
[5]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-JP5801011,2015,B2
[6]CurrentPatentAssignee:SHENZHENKEXINGBIOTECH;SHANDONGKEXINGBIOPRODUCTS-CN104761571,2017,B
[7]CurrentPatentAssignee:BEIJINGSUNNOVOPHARMACEUTICALRES-CN108484641,2018,A
[8]CurrentPatentAssignee:JILINYATAI(GROUP)CO.,LTD.-CN107641131,2018,A
[9]CurrentPatentAssignee:GAPIBIO;DONGBANGFTL;GABIBIO-JP2019/210273,2019,A
[10]CurrentPatentAssignee:GAPIBIO;DONGBANGFTL;GABIBIO-JP2019/210273,2019,A
[11]CurrentPatentAssignee:GAPIBIO;DONGBANGFTL;GABIBIO-JP2019/210273,2019,A
[12]CurrentPatentAssignee:INNERMONGOLIAJINGDONGPHARMACEUTICAL-CN111393456,2020,A
[13]CurrentPatentAssignee:INNERMONGOLIAJINGDONGPHARMACEUTICAL-CN111393456,2020,A
[14]CurrentPatentAssignee:GLENMARKPHARMACEUTICALSLTD-WO2021/1728,2021,A1
[15]CurrentPatentAssignee:BORYUNG;BORYUNGPHARMCO.,LTD.-WO2022/103239,2022,A1
[16]CurrentPatentAssignee:BORYUNG;BORYUNGPHARMCO.,LTD.-WO2022/103239,2022,A1
Title: Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Journal: Clinical pharmacokinetics 20160101
Title: Overview of the new oral anticoagulants: opportunities and challenges.
Journal: Arteriosclerosis, thrombosis, and vascular biology 20150501
Title: Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Journal: Seminars in thrombosis and hemostasis 20150301
Title: The role of factor Xa inhibitors in venous thromboembolism treatment.
Journal: Vascular health and risk management 20150101
Title: Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
Journal: Thrombosis and haemostasis 20121101
Title: Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Journal: Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20121001
Title: Oral direct factor Xa inhibitors.
Journal: Circulation research 20120928
Title: Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Journal: Thrombosis research 20120901
Title: The promise of novel direct oral anticoagulants.
Journal: Best practice & research. Clinical haematology 20120901
Title: Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Journal: Thrombosis and haemostasis 20120701
Title: Long-term benefits of preventing venous thromboembolic events.
Journal: Current medical research and opinion 20120601
Title: Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Journal: Critical pathways in cardiology 20120601
Title: In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
Journal: Thrombosis research 20120401
Title: Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.
Journal: Circulation journal : official journal of the Japanese Circulation Society 20120101
Title: Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Journal: Thrombosis and haemostasis 20111201
Title: Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.
Journal: Thrombosis and haemostasis 20111201
Title: [Current status and future of anti-Xa inhibitors].
Journal: Rinsho shinkeigaku = Clinical neurology 20111101
Title: The new oral anticoagulants.
Journal: Clinical medicine (London, England) 20111001
Title: Edoxaban for the prevention of thromboembolic events after surgery.
Journal: Drugs of today (Barcelona, Spain : 1998) 20111001
Title: [Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Journal: Giornale italiano di cardiologia (2006) 20110901
Title: Edoxaban: a new oral direct factor xa inhibitor.
Journal: Drugs 20110820
Title: Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.
Journal: Future cardiology 20110701
Title: [New anticoagulants in the prevention and treatment of venous thromboembolism].
Journal: Orvosi hetilap 20110619
Title: Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
Journal: Thrombosis and haemostasis 20110601
Title: Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
Journal: Thrombosis and haemostasis 20110301
Title: Factor Xa and thrombin as targets for new oral anticoagulants.
Journal: Thrombosis research 20110101
Title: Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Journal: Annual review of medicine 20110101
Title: Edoxaban tosylate.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101
Title: A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
Journal: Journal of thrombosis and haemostasis : JTH 20101101
Title: Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Journal: Thrombosis research 20101001
Title: Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Journal: American heart journal 20101001
Title: Factor Xa inhibitors: next-generation antithrombotic agents.
Journal: Journal of medicinal chemistry 20100909
Title: Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Journal: Thrombosis and haemostasis 20100901
Title: Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Journal: Thrombosis and haemostasis 20100901
Title: [Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100801
Title: Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Journal: Journal of clinical pharmacology 20100701
Title: Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Journal: Current opinion in cardiology 20100701
Title: New anticoagulants for atrial fibrillation.
Journal: Seminars in thrombosis and hemostasis 20090701
Title: DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
Journal: Journal of thrombosis and haemostasis : JTH 20080901
Title: New oral anticoagulants in atrial fibrillation.
Journal: European heart journal 20080101
